News & Resources

Neurodegeneration resulting in Alzheimer’s disease (AD) is the main type of dementia encountered and is a crisis not only for the patient and family but also for society [1]. Currently approved therapies provide only modest symptomatic improvement but fail to halt the unrelenting progression of the disease [2]. Research into the mechanisms underlying AD has…

Over the past year, several major pharmaceutical companies have scaled back or abandoned their neuropsychiatric drug development efforts, citing high costs and long development times with low success rates. A report from the Tufts Center for the Study of Drug Development reveals that only 8.2% of CNS drug candidates reach clinical use, compared to 15%…